Cargando…
Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study
INTRODUCTION: Interleukin-4 (IL-4) and interleukin-13 (IL-13) are two essential cytokines involved in the T helper 2 (Th2)-mediated inflammatory response to diseases, such as atopic dermatitis (AD). AK120 is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) directed against th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539271/ https://www.ncbi.nlm.nih.gov/pubmed/37668898 http://dx.doi.org/10.1007/s13555-023-01010-1 |
_version_ | 1785113461071544320 |
---|---|
author | Wynne, Christopher John Cole, Alexandra Lemech, Charlotte Wang, Guoqin Zhang, Yu Chen, Benchao Wang, Max Li, Baiyong Xia, Michelle Sinclair, Rodney |
author_facet | Wynne, Christopher John Cole, Alexandra Lemech, Charlotte Wang, Guoqin Zhang, Yu Chen, Benchao Wang, Max Li, Baiyong Xia, Michelle Sinclair, Rodney |
author_sort | Wynne, Christopher John |
collection | PubMed |
description | INTRODUCTION: Interleukin-4 (IL-4) and interleukin-13 (IL-13) are two essential cytokines involved in the T helper 2 (Th2)-mediated inflammatory response to diseases, such as atopic dermatitis (AD). AK120 is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) directed against the IL-4 receptor alpha (IL-4Rα) subunit shared by the IL-4 and IL-13 receptor complexes. This mAb inhibits the signaling of the IL-4 and IL-13 cytokines. METHODS: The study consisted of two parts. Part 1 was a single ascending dose (SAD) study with five cohorts (receiving 15, 50, 150, 300 or 600 mg of AK120, respectively) of healthy subjects; part 2 was a multiple ascending dose (MAD) study with four cohorts (receiving AK120 at doses of 300 mg once every 2 weeks [Q2W], 300 mg once weekly [QW], 150 mg QW or 75 mg QW) of subjects with AD. A total of 81 subjects (40 in part 1, 41 in part 2) were enrolled in the study. RESULTS: The compound was safe and well tolerated in both a SAD up to 600 mg in healthy subjects and in a MAD from 75 to 600 mg in subjects with AD. The exposure of AK120 increased in an approximately dose-dependent manner upon subcutaneous dosing. The levels of the biomarkers serum thymus and activation-regulated chemokine ligand 17 (TARC/CCL17) and immunoglobulin E decreased from baseline after AK120 administration, indicating the inhibition of the IL-4/IL-13 signaling pathways. AK120 showed improved Eczema Area and Severity Index (EASI) scores, and the proportion of subjects with Investigator Global Assessment (IGA) score 0/1 increased after AK120 treatment. CONCLUSIONS: AK120 exhibited an acceptable safety profile in healthy and AD subjects, and showed preliminary efficacy. These findings support the continued investigation of AK120 for treating AD. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identification number: NCT04256174. |
format | Online Article Text |
id | pubmed-10539271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-105392712023-09-30 Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study Wynne, Christopher John Cole, Alexandra Lemech, Charlotte Wang, Guoqin Zhang, Yu Chen, Benchao Wang, Max Li, Baiyong Xia, Michelle Sinclair, Rodney Dermatol Ther (Heidelb) Original Research INTRODUCTION: Interleukin-4 (IL-4) and interleukin-13 (IL-13) are two essential cytokines involved in the T helper 2 (Th2)-mediated inflammatory response to diseases, such as atopic dermatitis (AD). AK120 is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) directed against the IL-4 receptor alpha (IL-4Rα) subunit shared by the IL-4 and IL-13 receptor complexes. This mAb inhibits the signaling of the IL-4 and IL-13 cytokines. METHODS: The study consisted of two parts. Part 1 was a single ascending dose (SAD) study with five cohorts (receiving 15, 50, 150, 300 or 600 mg of AK120, respectively) of healthy subjects; part 2 was a multiple ascending dose (MAD) study with four cohorts (receiving AK120 at doses of 300 mg once every 2 weeks [Q2W], 300 mg once weekly [QW], 150 mg QW or 75 mg QW) of subjects with AD. A total of 81 subjects (40 in part 1, 41 in part 2) were enrolled in the study. RESULTS: The compound was safe and well tolerated in both a SAD up to 600 mg in healthy subjects and in a MAD from 75 to 600 mg in subjects with AD. The exposure of AK120 increased in an approximately dose-dependent manner upon subcutaneous dosing. The levels of the biomarkers serum thymus and activation-regulated chemokine ligand 17 (TARC/CCL17) and immunoglobulin E decreased from baseline after AK120 administration, indicating the inhibition of the IL-4/IL-13 signaling pathways. AK120 showed improved Eczema Area and Severity Index (EASI) scores, and the proportion of subjects with Investigator Global Assessment (IGA) score 0/1 increased after AK120 treatment. CONCLUSIONS: AK120 exhibited an acceptable safety profile in healthy and AD subjects, and showed preliminary efficacy. These findings support the continued investigation of AK120 for treating AD. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identification number: NCT04256174. Springer Healthcare 2023-09-05 /pmc/articles/PMC10539271/ /pubmed/37668898 http://dx.doi.org/10.1007/s13555-023-01010-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Wynne, Christopher John Cole, Alexandra Lemech, Charlotte Wang, Guoqin Zhang, Yu Chen, Benchao Wang, Max Li, Baiyong Xia, Michelle Sinclair, Rodney Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study |
title | Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study |
title_full | Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study |
title_fullStr | Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study |
title_full_unstemmed | Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study |
title_short | Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study |
title_sort | safety, pharmacokinetics and preliminary efficacy of il4-rα monoclonal antibody ak120 in both healthy and atopic dermatitis subjects: a phase i, randomized, two-part, double-blind, placebo-controlled, dose-escalation, first-in-human clinical study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539271/ https://www.ncbi.nlm.nih.gov/pubmed/37668898 http://dx.doi.org/10.1007/s13555-023-01010-1 |
work_keys_str_mv | AT wynnechristopherjohn safetypharmacokineticsandpreliminaryefficacyofil4ramonoclonalantibodyak120inbothhealthyandatopicdermatitissubjectsaphaseirandomizedtwopartdoubleblindplacebocontrolleddoseescalationfirstinhumanclinicalstudy AT colealexandra safetypharmacokineticsandpreliminaryefficacyofil4ramonoclonalantibodyak120inbothhealthyandatopicdermatitissubjectsaphaseirandomizedtwopartdoubleblindplacebocontrolleddoseescalationfirstinhumanclinicalstudy AT lemechcharlotte safetypharmacokineticsandpreliminaryefficacyofil4ramonoclonalantibodyak120inbothhealthyandatopicdermatitissubjectsaphaseirandomizedtwopartdoubleblindplacebocontrolleddoseescalationfirstinhumanclinicalstudy AT wangguoqin safetypharmacokineticsandpreliminaryefficacyofil4ramonoclonalantibodyak120inbothhealthyandatopicdermatitissubjectsaphaseirandomizedtwopartdoubleblindplacebocontrolleddoseescalationfirstinhumanclinicalstudy AT zhangyu safetypharmacokineticsandpreliminaryefficacyofil4ramonoclonalantibodyak120inbothhealthyandatopicdermatitissubjectsaphaseirandomizedtwopartdoubleblindplacebocontrolleddoseescalationfirstinhumanclinicalstudy AT chenbenchao safetypharmacokineticsandpreliminaryefficacyofil4ramonoclonalantibodyak120inbothhealthyandatopicdermatitissubjectsaphaseirandomizedtwopartdoubleblindplacebocontrolleddoseescalationfirstinhumanclinicalstudy AT wangmax safetypharmacokineticsandpreliminaryefficacyofil4ramonoclonalantibodyak120inbothhealthyandatopicdermatitissubjectsaphaseirandomizedtwopartdoubleblindplacebocontrolleddoseescalationfirstinhumanclinicalstudy AT libaiyong safetypharmacokineticsandpreliminaryefficacyofil4ramonoclonalantibodyak120inbothhealthyandatopicdermatitissubjectsaphaseirandomizedtwopartdoubleblindplacebocontrolleddoseescalationfirstinhumanclinicalstudy AT xiamichelle safetypharmacokineticsandpreliminaryefficacyofil4ramonoclonalantibodyak120inbothhealthyandatopicdermatitissubjectsaphaseirandomizedtwopartdoubleblindplacebocontrolleddoseescalationfirstinhumanclinicalstudy AT sinclairrodney safetypharmacokineticsandpreliminaryefficacyofil4ramonoclonalantibodyak120inbothhealthyandatopicdermatitissubjectsaphaseirandomizedtwopartdoubleblindplacebocontrolleddoseescalationfirstinhumanclinicalstudy |